Allotera Therapeutics has welcomed Aaron Vernon as Acting Chief Technology Officer, supporting the company’s technical operations as it advances Sofi-cel, its off-the-shelf CAR-T cell therapy for T-cell cancers. Vernon joins following Allotera’s new name, additional financing, and the opening of the MRD-positive cohort in its T-RRex study.
About Aaron Vernon
Vernon is a cell and gene therapy executive with more than two decades of experience in technical operations, spanning CMC strategy, manufacturing, supply chain, quality, and MSAT. He is the owner and principal of ACE Biopharm Consulting LLC and serves as fractional Chief Manufacturing Officer at March Biosciences. Previously, he was Chief Manufacturing Officer at Quell Therapeutics and Vice President of Technical Operations at TCR² Therapeutics.
Vernon holds a bachelor’s degree in mechanical engineering and applied mechanics from the University of Pennsylvania and a postgraduate certificate in process business management from the University of Warwick’s WMG.
About Allotera Therapeutics
Allotera Therapeutics, formerly Wugen, is a pivotal-stage biotechnology company based in St. Louis, Missouri, developing allogeneic, off-the-shelf CAR-T cell therapies for cancer. Its lead candidate, Sofi-cel, is a CD7-targeted CAR-T therapy in a global pivotal study for relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. The company took its new name in July 2026 alongside the closing of a $35 million financing round.6 alongside the closing of a $35 million financing round.
